Taken together, our data suggest that DEC2, which was shown to promote HIF-1α degradation in other tumors, may facilitate HIF-1 activation and metabolic reprograming in osteosarcomas, and that HIF-1 activation may, in turn, promote DEC2 expression, forming a vicious cycle. Here, BHLHE41 is linked to osteosarcoma.